Pediatric drug-resistant tuberculosis: A global perspective

Pediatric Drugs

Volumn 13, Issue 6, 2011, Pages 349-355

  Reubenson, Gary ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BRAIN DISEASE; CHILD; CONVULSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE TRANSMISSION; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAIR DISCOLORATION; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOTHYROIDISM; INSOMNIA; LACTIC ACIDOSIS; LIVER TOXICITY; NEPHROTOXICITY; OPTIC NEURITIS; OTOTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PHLEBITIS; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RASH; REVIEW; SKIN DISCOLORATION; SKIN MANIFESTATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CHILD; CHILD HEALTH SERVICES; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 80054725767     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11593160-000000000-00000     Document Type: Review

References (41)

1. World Health Organization. WHO report 2010: global tuberculosis control. WHO/HTM/TB/2010.7. Geneva: World Health Organization, 2010
2. World Health Organization. Childhood tuberculosis [online]. Available from URL: http://www.who.int/tb/challenges/children/en/index.html [Accessed 2011 Aug 30]
3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva: World Health Organization, 2010
4. Zur Wiesch PA, Kouyos R, Engelstädter J, et al. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 2011 Mar; 11: 236-47
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva: World Health Organization, 2008
6. Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev 2011 Mar; 12 (1): 31-8
7. Marais BJ, Obihara CC, Warren RM, et al. The burden of childhood tuberculosis: a public health perspective. Int J Tuberc LungDis 2005 Dec; 9: 1305-13 (Pubitemid 43265138)
8. Schaaf HS, Marais BJ, Hesseling AC, et al. Surveillance of antituberculosis drug resistance amongst children from the Western Cape Province of South Africa: an upward trend. Am J Public Health 2009 Aug; 99 (8): 1486-90
9. Fairlie L, Beylis NC, Reubenson G, et al. High prevalence of multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011; 11: 28
10. Al-Dabbagh M, Lapphra K, McGloin R, et al. Drug-resistant tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011 Jun; 30 (6): 501-5
11. Marlowe EM, Novak-Weekley SM, Cumpio J, et al. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 2011 Apr; 49 (4): 1621-3
12. Hillemann D, Rüsch-Gerdes S, Boehme C, et al. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpertMTB/RIF system. J Clin Microbiol 2011 Apr; 49 (4): 1202-5
13. Moure R, Muñoz L, Torres M. Rapid detection of Mycobacterium tuberculosis complex and rifampin resistance in smear-negative clinical samples by use of an integrated real-time PCR method. JClin Microbiol 2011 Mar; 49 (3): 1137-9
14. Niemz A, Ferguson TM, Boyle DS. Point-of-care nucleic acid testing for infectious diseases. Trends Biotechnol 2011 May; 29: 240-50
15. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the XpertMTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital inCape Town, South Africa: a descriptive study. Lancet Infect Dis. Epub 2011 Jul 15
16. Halse TA, Edwards J, Cunningham PL, et al. Combined real-time PCR and rpoB gene pyrosequencing for rapid identification of Mycobacterium tuberculosis and determination of rifampin resistance directly in clinical specimens. J Clin Microbiol 2010 Apr; 48 (4): 1182-8
17. Parsons LM, Somoskövi A, Gutierrez C, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011 Apr; 24 (2): 314-50
18. Pai M. Improving TB diagnosis: difference between knowing the path and walking the path. Expert Rev Mol Diagn 2011 Apr; 11 (3): 241-4
19. OGrady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011 May; 17: 134-41
20. Zar HJ, Connell TG, Nicol M. Diagnosis of pulmonary tuberculosis in children: new advances. Expert Rev Anti Infect Ther 2010 Mar; 8: 277-88
21. Nicol MP, Zar HJ. New specimens and laboratory diagnostics for childhood pulmonaryTB: progress and prospects. Paediatr Respir Rev 2011Mar; 12: 16-21
22. World Health Organization. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva: World Health Organization, 2010 Dec 6 [online]. Available from URL: http://www.who.int/tb/laboratory/roadmap-xpert- mtb-rif.pdf [Accessed 2011 Aug 30]
23. Marais BJ, Rabie H, Cotton MF. TB and HIV in children-advances in prevention and management. Paediatr Respir Rev 2011 Mar; 12: 39-45
24. Bonora S, Di Perri G. Interactions between antiretroviral agents and those used to treat tuberculosis. Curr Opin HIV AIDS 2008 May; 3 (3): 306-12 (Pubitemid 351521015)
25. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14 (8): 1039-43
26. Stöhr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13 (5): 675-85
27. World Health Organization. WHO model formulary for children. Geneva: World Health Organization, 2010 [online]. Available from URL: http://whqlibdoc.who.int/publications/2010/9789241599320-eng.pdf [Accessed 2011 Aug 30]
28. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of highdose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008 Feb; 12 (2): 139-45 (Pubitemid 351212404)
29. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010 May 22; 375 (9728): 1798-807
30. Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 2009 Nov; 14 (11): 1329-37
31. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 672-82
32. International Union Against Tuberculosis and Lung Disease/World Health Organization. Guidance for national tuberculosis and HIV programmes on the management of tuberculosis in HIV-infected children: recommendations for a public health approach. Paris: The Union, 2010 [online]. Available from URL: http://www.theunion.org/index.php/resources/scientific-publications/item/index. php?id=630&cid=759&fid=57&task=download&option=com-flexi content&Itemid=43&lang=en [Accessed 2011 Aug 30]
33. Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-9 (Pubitemid 46071247)
34. World Health Organization. Management of MDR-TB: a field guide. A companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). WHO/HTM/TB/2008.402a. Geneva: World Health Organization, 2009
35. World Health Organization. Green Light Committee initiative: scaling up the global fight against MDR-TB. WHO/HTM/TB/2010.14. Geneva. World Health Organization, 2010
36. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature 2011 Jan 27; 469 (7331): 483-90
37. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep 2010 Aug; 7: 143-51
38. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010 Jun 12; 375 (9731): 2100-9
39. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009 Apr 4; 373 (9670): 1183-9
40. Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Arch Dis Child 2011 Sep; 96 (9): 851-6
41. Hawkridge T, Mahomed H. Prospects for a new, safer and more effective TB vaccine. Paediatr Respir Rev 2011 Mar; 12 (1): 46-51